

YODA Project # 2017-2651

Title: Do alpha blockers and 5 α -reductase inhibitors influence survival, toxicities and urinary function in patients treated with abiraterone?

Objective: To assess the association between alpha blocker and 5-ARI intake and survival, need for palliative TURP or ureter stent placement and change in urinary symptoms or incidence of urinary tract infections.

Methods Used:

Study Design: Post-hoc analysis of two randomized controlled phase 3 studies.

Participants Patients on abiraterone in the chemotherapy-naïve and post-chemotherapy CRPC setting.

Main Outcome Measure(s): Radiographic progression free (rPFCS) and overall survival (OS), toxicities as well as on urinary function (need for palliative TURP or ureter stent placement and change in urinary symptoms or incidence of urinary tract infections)

Statistical Analysis: Uni- and multivariable Cox regression analysis, Kaplan–Meier plots and log-rank tests

Results: First our group unsuccessfully tried to reproduce the results of the published data of the COU-AA-301/302 trials.

Conclusions: Our group was not able to identify the variables of interest or reproduce the findings of previous publications. We therefore did not proceed with our planned analyses.